Volume 13 Supplement 1
Decreased vascular endothelial growth factor expression in lung tissue during acute respiratory distress syndrome
© Azamfirei et al; licensee BioMed Central Ltd. 2009
Published: 13 March 2009
Endothelial injury is an important prognostic factor in acute respiratory distress syndrome (ARDS) [1, 2]. Vascular endothelial growth factor (VEGF) plays a critical role in endothelial destruction and angiogenesis . The expression of VEGF in ARDS varies, depending on epithelial and endothelial damage [4, 5]. The objective of this study was to investigate the expression of VEGF in lung tissue from ARDS patients.
Lung specimens were obtained by autopsy from 10 patients with severe ARDS and were compared with a control group of 10 non-ARDS patients autopsied. All lung samples were stained for standard histopathological analysis and for immunohistochemical methods using a specific mouse monoclonal antibody.
Compared with expression in non-ARDS control individuals, pulmonary expression of VEGF was significantly decreased (P < 0.001) in ARDS patients. Alveolar macrophages were similarly immunopositive in both groups. No differences were noted with regard to the individual patient's characteristics (age, gender, period of ARDS condition, number of ICU days).
A decrease in alveolar type II cellularity, due to apoptosis, has been observed during ARDS that may reduce the production of VEGF in the alveolar space and may participate in the decrease in lung perfusion.
Research Grant No. 136/IDEI from the National Authority of Scientific Research, Romania.
- Medford ARL, Millar AB: Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm? Thorax 2006, 61: 621. 10.1136/thx.2005.040204View ArticleGoogle Scholar
- Dvorak HF: Angiogenesis: update 2005. J Thromb Haemost 2005, 3: 1835-1842. 10.1111/j.1538-7836.2005.01361.xView ArticleGoogle Scholar
- Gerber HP, Wu X, Yu L, Wiesmann C, et al.: Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci USA 2007, 104: 3478-3483. 10.1073/pnas.0611492104View ArticleGoogle Scholar
- Fehrenbach H: Development of the pulmonary surfactant system. Pneumologie 2007, 61: 488. 10.1055/s-2007-959227View ArticleGoogle Scholar
- Shibuya M: Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006, 39: 469-478.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd.